David Odde named to AIMBE board
April 12, 2026 — The American Institute for Medical and Biological Engineering (AIMBE) has announced David Odde has joined its Board of Directors as Director At-Large.
Odde, along with others on the board, will take office following the conclusion of the AIMBE Annual Event, taking place April 11–13, 2026 in Washington, D.C.
Odde states:
“As I enter the later stages of my career, I am concerned about the next chapter of biomedical engineering In the United States. The American people have generously supported our mission throughout my career, and our country has benefited from the investment in terms of both life-saving technologies and economic opportunity/impact. I will strive to further advance biomedical engineering into the next exciting phase, and will seek to build public, private, and political support for our efforts. I plan to be present in Washington or wherever I can effectively advocate for biomedical engineering. My own story is one of personally benefiting from biomedical technology. In 2023 I had a major stroke that was effectively treated by mechanical thrombectomy combined with stents. Earlier in my career I was inspired by engineers like Shu Chien and Bob Nerem who successfully advocated for biomedical engineering generally and the establishment of NIBIB specifically through AIMBE. We have all benefited from their efforts and I would like to do my share at this stage in my career to similarly advance biomedical engineering.”
As AIMBE states in a news release:
These elected leaders bring a wealth of expertise and passion to AIMBE’s mission of advancing medical and biological engineering through advocacy, policy engagement, and professional development. Their leadership will be instrumental in driving AIMBE’s strategic initiatives forward at this critical time for science and engineering.
“We are excited to welcome these new leaders to AIMBE’s Board of Directors,” said AIMBE President Lola Eniola-Adefeso, Ph.D. “Their diverse expertise and dedication will help shape the future of biomedical innovation and advocacy.”